Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

Fig. 5

Comparisons of the survival of hepatocellular carcinoma (HCC) patients with low cytokine levels. a Kaplan-Meier survival of HCC patients with low serum VEGF-A levels treated with sorafenib or hepatic arterial infusion chemotherapy (HAIC). b Kaplan-Meier survival curves of HCC patients with low serum IL-8 levels treated with sorafenib or HAIC. c Kaplan-Meier survival curves of HCC patients with low serum IL-5 levels treated with sorafenib or HAIC

Back to article page